RxDoctor Payments Data

Theodore Korty, DO

Rheumatology · Evansville, INNPI 1134580863

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 435 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 41.9% of the total.

$8,442in general payments, 2019–2025

Across 435 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Amgen$2K
  • UCB, Inc.$742
  • Novartis$469
  • Genentech USA, Inc.$321
  • GSK$191
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$8,22597%
  • Education$2163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,442 in reported general payments places this provider in the 75th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$905,228
Medicare patients
295
Services billed
63,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept20$206,502
OtezlaApremilast11$51,231
Hydroxychloroquine Sulfate324$10,122
MethotrexateMethotrexate Sodium267$3,959
Leflunomide43$2,751
Celecoxib64$1,868
Colchicine27$1,818
Prednisone246$1,379
Allopurinol141$1,293
Minocycline Hcl17$1,228
Sulfasalazine64$1,196
Duloxetine Hcl47$862
Probenecid11$682
Nabumetone31$623
Alendronate Sodium83$522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,771$51,23111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →